NCT05953883Active, not recruiting
Proteogenomic Signatures Analysis In Ovarian Cancer
Proteogenomic Signatures Analysis In Ovarian Cancer, Longitudinal Modification On Tumor Tissue Before And After Platinum-Based Neoadjuvant Chemotherapy
Source: ClinicalTrials.gov · Last updated 4 Mar 2025
Brief summary (registry, in English)
Proteogenomic analysis to detect individual platinum-induced modifications on tumor tissue of HGSC according to chemotherapy response score (CRS), using a combined approach of High resolution liquid chromatography mass Spectrometry based platform (HR-LC-MS/MS and advanced immunometric methods on illumine platform); multiple supervised machine learning algorithms will be used to discover proteogenomic signatures and biological processes associated with platinum modification during the neoadjuvant chemotherapy treatment. These results contribute to precision medicine by building an accurate proteogenomic profile of ovarian cancer, in order to better understand the underlying mechanisms of different chemotherapy response among affected patients.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 24 (actual)
- First submitted
- 21 Jun 2023
- Start date
- 17 Nov 2022
- Primary completion date
- 17 Nov 2023
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Diseases
- Ovarian cancer
- NCT number
- NCT05953883
What you commit to
- Study type: Interventional
- Participants enrolled: 24
- From 17 Nov 2022 to the primary completion date, 17 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (\> 10 mg equivalent prednisone/daily) or any other form of immunosuppressive therapy within 7 days prior to the enrollment;
- Previous diagnosis of cancer within 5 years.
Other
- Non-serous histology at frozen section;
Who the study is looking for
- Newly diagnosed advanced International Federation of Gynecology and Obstetrics (FIGO) stage III A or greater epithelial ovarian cancer addressed to neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS);
- Availability of freshly frozen tissue and FFPE tissue from both exploratory laparoscopy (baseline) and IDS;
- Age between 18 and 80 years;
- Estimated life expectancy of at least 4 weeks;
- Signed informed consent
Age in the registry: 18 years to 80 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS Coordinator of this site? Confirm its status | Rome | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.